CDKN2A and atherosclerosis: In particular, ANRIL is important for regulation of two tumor suppressor genes, cyclin-dependent kinase inhibitors A and B in CDKN2A/B locus that are involved in atherosclerosis in terms of thrombogenesis, vascular remodeling or repair, and plaque stability [32, 42].